专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

91. 发明公开

EP3164417A1 BISPECIFIC HETERODIMERIC DIABODIES AND USES THEREOF 审中-公开
标题翻译：双特异性异二聚体糖尿病及其用途
公开(公告)号：EP3164417A1
公开(公告)日：2017-05-10
申请号：EP15741347.7
申请日：2015-06-26
申请人： Pfizer Inc.
发明人： MAY, Chad Michael , ROOT, Adam Reid , BRADY, William A. , TCHISTIAKOVA, Lioudmila Gennadievna , MOSYAK, Lidia , BLOOM, Laird , MOORE, Paul A. , JOHNSON, Leslie S.
IPC分类号： C07K16/28
CPC分类号： C07K16/468 , C07K16/18 , C07K16/28 , C07K16/2809 , C07K2317/31 , C07K2317/524 , C07K2317/526 , C07K2317/56 , C07K2317/565 , C07K2317/626 , C07K2317/72 , C07K2317/732 , C07K2317/76 , C07K2317/94
摘要： Bispecific heterodimeric diabody molecules and uses thereof in the treatment of cancer. The bispecific heterodimeric diabody molecules comprise two polypeptide chains that associate to form two epitope binding sites recognizing the P-cadherin tumor cell associated antigen and the CD3 T cell antigen.
摘要翻译：双特异性异二聚体双抗体分子及其在治疗癌症中的用途。双特异性异二聚体双抗体分子包含两条多肽链，其结合形成识别P-钙粘蛋白肿瘤细胞相关抗原和CD3T细胞抗原的两个表位结合位点。

92. 发明公开

EP3160999A2 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THAT SPECIFICALLY BIND TO MICROTUBULE-ASSOCIATED PROTEIN TAU 审中-公开
公开(公告)号：EP3160999A2
公开(公告)日：2017-05-03
申请号：EP15731936.9
申请日：2015-06-26
申请人： Janssen Vaccines & Prevention B.V.
发明人： WADIA, Jehangir , PASCUAL, Gabriel , WILLIAMSON, Robert, Anthony , RADOSEVIC, Katarina , GOUDSMIT, Jaap
IPC分类号： C07K16/18 , A61K39/395
CPC分类号： C07K16/18 , A61K39/395 , C07K2317/21 , C07K2317/24 , C07K2317/30 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/72 , C07K2317/94 , G01N33/6896 , G01N2333/47 , G01N2800/2821
摘要： The disclosure relates to antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau. The disclosure also relates to diagnostic, prophylactic and therapeutic methods using anti-tau antibodies.

93. 发明公开

EP3160502A2 ANTI-IL4-IL 13 BISPECIFIC ANTIBODIES 审中-公开
标题翻译：抗-IL4-IL 13双特异性抗体
公开(公告)号：EP3160502A2
公开(公告)日：2017-05-03
申请号：EP15775787.3
申请日：2015-06-26
申请人： SANOFI
发明人： ESPERET, Corrine , JAGERSCHMIET, Alexandre , SOUBRANE, Christina , SUBRAMANIAM, Arun
IPC分类号： A61K39/395
CPC分类号： C07K16/247 , A61K39/02 , A61K39/395 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K14/521 , C07K16/244 , C07K16/468 , C07K2317/31 , C07K2317/33 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2317/94 , G01N33/6893 , G01N2333/521 , G01N2800/52
摘要： Disclosed herein are safe doses of dual-V-region antibody-like binding proteins or fragments thereof, as well as methods for assessing binding of dual-V- region antibody-like proteins or fragments thereof to their targets, and methods of treating idiopathic pulmonary fibrosis (IPF) by administering safe doses of dual-V- region antibody-like binding proteins or fragments thereof. In some embodiments, the dual-V-region antibody-like binding proteins or fragments thereof bind both IL-4 and IL-13.
摘要翻译：本文公开了安全剂量的双V区抗体样结合蛋白或其片段，以及评估双V区抗体样蛋白或其片段与其靶标的结合的方法，以及治疗特发性肺通过施用安全剂量的双V区抗体样结合蛋白或其片段来进行纤维化（IPF）。在一些实施方案中，双V区抗体样结合蛋白或其片段结合IL-4和IL-13两者。

94. 发明公开

EP3035956A4 BI-SPECIFIC MONOVALENT DIABODIES THAT ARE CAPABLE OF BINDING TO GPA33 AND CD3, AND USES THEREOF 有权转让
标题翻译： BISPEZIFISCHE MONOVALENTE DIABODIES MITFÄHIGKEITZUR BINDUNG VON GPA33 UND CD3 SOWIE VERWENDUNGEN DAVON
公开(公告)号：EP3035956A4
公开(公告)日：2017-05-03
申请号：EP14837376
申请日：2014-08-20
申请人： MACROGENICS INC
发明人： MOORE PAUL A , LI JONATHAN , CHEN FRANCINE ZHIFEN , JOHNSON LESLIE S , SHAH KALPANA , BONVINI EZIO
IPC分类号： C07K16/28 , A61K39/00
CPC分类号： C07K16/28 , A61K2039/505 , A61K2039/545 , C07K16/2803 , C07K16/2809 , C07K16/3046 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/35 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/56 , C07K2317/624 , C07K2317/626 , C07K2317/64 , C07K2317/73 , C07K2317/732 , C07K2317/92 , C07K2317/94 , C07K2319/31
摘要： The present invention is directed to bi-specific monovalent diabodies that comprise two polypeptide chains and which possess at least one binding site specific for an epitope of CD3 and one binding site specific for an epitope of gpA33 (i.e., a "gpA33 x CD3 bi-specific monovalent diabody"). The present invention also is directed to bi-specific monovalent diabodies that comprise an immunoglobulin Fc domain ("bi-specific monovalent Fc diabodies") and are composed of three polypeptide chains and which possess at least one binding site specific for an epitope of gpA33 and one binding site specific for an epitope of CD3 ( i.e ., a "gpA33 x CD3 bi-specific monovalent Fc diabody"). The bi-specific monovalent diabodies and bi-specific monovalent Fc diabodies of the present invention are capable of simultaneous binding to gpA33 and CD3. The invention is directed to pharmaceutical compositions that contain such bi-specific monovalent diabodies or such bi-specific monovalent Fc diabodies. The invention is additionally directed to methods for the use of such diabodies in the treatment of cancer and other diseases and conditions.
摘要翻译：本发明涉及双特异性单价双抗体，其包含两条多肽链并且具有对CD3表位特异的至少一个结合位点和对gpA33表位具有特异性的一个结合位点（即，“gpA33xCD3双链抗体” 特异性单价双抗体“）。本发明还涉及包含免疫球蛋白Fc结构域（“双特异性单价Fc双抗体”）并且由三条多肽链组成并且具有至少一个对gpA33的表位具有特异性的结合位点的双特异性单价双抗体和一个对CD3表位特异的结合位点（即，“gpA33xCD3双特异性单价Fc双抗体”）。本发明的双特异性单价双抗体和双特异性单价Fc双抗体能够同时结合gpA33和CD3。本发明涉及含有此类双特异性单价双抗体或此类双特异性单价Fc双抗体的药物组合物。本发明还涉及使用这种双抗体治疗癌症和其他疾病和病症的方法。

95. 发明授权

EP2552955B1 ANTIBODIES WITH MODIFIED AFFINITY TO FCRN THAT PROMOTE ANTIGEN CLEARANCE 有权
标题翻译： ANTIKÖRPERMITVERÄNDERTERAFFINITÄTZU FCRN ZUR GESTEIGERTEN ANTIGEN-BESEITIGUNG
公开(公告)号：EP2552955B1
公开(公告)日：2017-05-03
申请号：EP11714860
申请日：2011-03-30
申请人： CHUGAI PHARMACEUTICAL CO LTD
发明人： IGAWA TOMOYUKI , ISHII SHINYA , MAEDA ATSUHIKO , NAKAI TAKASHI
IPC分类号： C07K16/00
CPC分类号： C07K16/18 , A61K2039/505 , A61K2039/545 , C07K14/70535 , C07K16/248 , C07K16/28 , C07K16/2866 , C07K16/4241 , C07K2317/24 , C07K2317/31 , C07K2317/52 , C07K2317/71 , C07K2317/72 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , C07K2319/30
摘要： An objective of the present invention is to provide methods for facilitating antigen-binding molecule-mediated antigen uptake into cells, methods for facilitating the reduction of antigen concentration in plasma, methods for increasing the number of antigens to which a single antigen-binding molecule can bind, methods for improving pharmacokinetics of antigen-binding molecules, antigen-binding molecules improved for facilitated antigen uptake into cells, antigen-binding molecules capable of facilitating the reduction of antigen concentration in plasma, antigen-binding molecules capable of repeatedly binding to antigens, antigen-binding molecules with improved pharmacokinetics, pharmaceutical compositions comprising such an antigen-binding molecule, and methods for producing those described above. The present inventors discovered that antigen uptake into cells is facilitated by an antibody having human FcRn-binding activity at the plasma pH and a lower antigen-binding activity at the early endosomal pH than at the plasma pH; such antibodies can increase the number of antigens to which a single antibody molecule can bind; the reduction of antigen in plasma can be facilitated by administering such an antibody; and antibody pharmacokinetics can be improved by using such antibodies.
摘要翻译：本发明的一个目的是提供促进抗原结合分子介导的抗原摄入细胞的方法，促进血浆中抗原浓度降低的方法，增加单一抗原结合分子可以将抗原数量增加的方法改善抗原结合分子的药代动力学的方法，为促进抗原摄取进入细胞而改善的抗原结合分子，能够促进血浆中抗原浓度降低的抗原结合分子，能够重复结合抗原的抗原结合分子，具有改善的药代动力学的抗原结合分子，包含这种抗原结合分子的药物组合物，以及用于生产上述那些的方法。本发明人发现，在血浆pH下具有人FcRn结合活性的抗体和早期内体pH下的抗原结合活性低于血浆pH的抗体促进了抗原向细胞的摄取; 这样的抗体可以增加单个抗体分子可以结合的抗原的数量; 通过施用这种抗体可以促进血浆中抗原的减少; 并且通过使用这样的抗体可以改善抗体药代动力学。

96. 发明公开

EP3157563A1 COMPOSITIONS AND METHODS FOR SAFE AND EFFECTIVE IMMUNOTHERAPY 审中-公开
标题翻译：安全有效的免疫疗法的组合物和方法
公开(公告)号：EP3157563A1
公开(公告)日：2017-04-26
申请号：EP15811201.1
申请日：2015-06-23
申请人： TheraMAB LLC
发明人： MATSKEVICH, Alexey , TYRSIN, Dmitry , CHUVPILO, Sergey
IPC分类号： A61K39/395 , C07K16/28 , A61P19/02 , A61P37/02
CPC分类号： C07K16/2818 , A61K9/0019 , A61K31/573 , A61K39/3955 , A61K2039/505 , A61K2039/545 , C07K2317/24 , C07K2317/73 , C07K2317/75 , C07K2317/94 , A61K2300/00 , A61K39/395
摘要： This invention relates to methods and compositions that are useful for the treatment of various diseases, including inflammatory diseases. The invention relates to, in part, doses and regimens for safer immunotherapy in the treatment of these diseases, including, for example, safe treatments with anti-CD28 antibodies.
摘要翻译：本发明涉及可用于治疗各种疾病（包括炎性疾病）的方法和组合物。本发明部分涉及用于治疗这些疾病的更安全免疫疗法的剂量和方案，包括例如用抗CD28抗体的安全治疗。

97. 发明公开

EP3043780A4 NOVEL DELIVERY COMPOSITIONS AND METHODS OF USING SAME 审中-公开
标题翻译： NEUARTIGE FREISETZUNGSZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON
公开(公告)号：EP3043780A4
公开(公告)日：2017-04-26
申请号：EP14844262
申请日：2014-09-12
申请人： UNIV JEFFERSON
发明人： SHOYELE SUNDAY A , SRINIVASAN ASHA R
IPC分类号： A61K9/14 , A61K9/50 , A61K38/16 , C07K16/00 , C07K16/22
CPC分类号： A61K39/3955 , A61K9/0073 , A61K9/145 , A61K9/146 , A61K9/1641 , A61K9/5123 , A61K9/5146 , A61K9/5192 , A61K31/713 , A61K45/06 , C07K16/00 , C07K16/18 , C07K16/22 , C07K2317/21 , C07K2317/24 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , C12N15/111 , C12N15/113 , C12N15/1135 , C12N2310/14 , C12N2320/32
摘要： This invention provides compositions comprising at least one protein nanoparticle comprising a protein and a non-ionic surfactant. In certain embodiments, the nanoparticle further comprises a therapeutic agent, such as a siRNA. In other embodiments, the nanoparticle further comprises a cell surface receptor ligand. Also included in the invention are methods of preparing the compositions of the present invention, and methods of treating, ameliorating or preventing a disease or disorder in a subject in need thereof using the compositions of the present invention.
摘要翻译：本发明提供了包含至少一种包含蛋白质和非离子表面活性剂的蛋白质纳米颗粒的组合物。在某些实施方案中，纳米颗粒还包含治疗剂，例如siRNA。在其他实施方案中，纳米颗粒还包含细胞表面受体配体。本发明还包括制备本发明组合物的方法，以及使用本发明组合物治疗，改善或预防有需要的受试者的疾病或病症的方法。

98. 发明授权

EP2139918B1 ANTIBODY SINGLE VARIABLE DOMAINS AGAINST SERUM ALBUMIN 有权
标题翻译：变单域抗体针对血清白蛋白
公开(公告)号：EP2139918B1
公开(公告)日：2017-04-19
申请号：EP08702087.1
申请日：2008-02-08
申请人： Domantis Limited
发明人： TOMLINSON, Ian , JESPERS, Laurent , CLUBE, Jasper , HOLT, Lucy , SCHON, Oliver
IPC分类号： C07K16/18
CPC分类号： C07K16/18 , A61K47/6843 , C07K16/241 , C07K16/2878 , C07K2317/31 , C07K2317/34 , C07K2317/35 , C07K2317/53 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/624 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2318/20 , C07K2319/00 , C07K2319/01 , C07K2319/31

99. 发明授权

EP2324061B1 MULTISPECIFIC ANTIBODIES 有权
标题翻译：多特异性抗体
公开(公告)号：EP2324061B1
公开(公告)日：2017-04-12
申请号：EP09792139.9
申请日：2009-09-01
申请人： F. Hoffmann-La Roche AG
发明人： BOSTROM, Jenny M. , FUH, Germaine
IPC分类号： C07K16/28 , C07K16/22 , C07K16/32 , C07K16/46 , C12N15/13 , A61K39/395 , A61P35/00
CPC分类号： C07K16/32 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/22 , C07K16/2863 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/92 , C07K2317/94

100. 发明公开

EP3150225A1 COMPOSITION D'IMMUNOGLOBULINES HUMAINES CONCENTREES 审中-公开
标题翻译： ZUSAMMENSETZUNG AUS HUMANEM IMMUNGLOBULINKONZENTRAT
公开(公告)号：EP3150225A1
公开(公告)日：2017-04-05
申请号：EP16197817.6
申请日：2011-07-18
申请人： Laboratoire Français du Fractionnement et des Biotechnologies
发明人： HUILLE, Sylvain , COHEN-TANNOUDJI, Laetitia , ARVIS, Florence , PAILLARD, Alexandra
IPC分类号： A61K39/395 , C07K16/06 , A61K47/00
CPC分类号： A61K39/39591 , A61K9/0019 , A61K39/395 , A61K47/10 , A61K47/12 , A61K47/183 , A61K47/26 , A61K2039/505 , C07K16/06 , C07K2317/94
摘要： L'invention concerne une composition d'immunoglobulines G humaines caractérisée en ce que la concentration en immunoglobulines G humaines est d'au moins 230g/L, utile notamment pour une administration par la voie sous-cutanée.
摘要翻译：本发明涉及人免疫球蛋白G组合物，其特征在于人免疫球蛋白G浓度为至少230g / l，其特别用于皮下给药。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式